PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
PTC Therapeutics (PTCT) Misses Q3 EPS by 22c
November 2, 2017 5:03 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($0.82), $0.22 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $41.85 million versus the consensus estimate of $45.03 million.
2017 Guidance:
Translarna net sales guidance for 2017 is anticipated to be between $120 and $140 million. We... More